The antiviral activity of kaempferol against pseudorabies virus in mice

Abstract

Background Pseudorabies virus (PRV), a member of the Alphaherpesviruses , is one of the most important pathogens that harm the global pig industry. Accumulated evidence indicated that PRV could infect humans under certain circumstances, inducing severe clinical symptoms such as acute human encephalitis. Currently, there are no antiviral drugs to treat PRV infections, and vaccines available only for swine could not provide full protection. Thus, new control measures are urgently needed. Results In the present study, kaempferol exhibited anti-PRV activity in mice through improving survival rate by 22.22\u2009%, which was higher than acyclovir (Positive control) with the survival rate of 16.67\u2009% at 6 days post infection (dpi); meanwhile, the survival rate was 0\u2009% at 6 dpi in the infected-untreated group. Kaempferol could inhibit the virus replication in the brain, lung, kidney, heart and spleen, especially the viral gene copies were reduced by over 700-fold in the brain, which was further confirmed by immunohistochemical examination. The pathogenic changes induced by PRV infection in these organs were also alleviated. The transcription of the only immediate-early gene IE180 in the brain was significantly inhibited by kaempferol, leading to the decreased transcriptional levels of the early genes (EPO and TK). The expression of latency-associated transcript (LAT) was also inhibited in the brain, which suggested that kaempferol could inhibit PRV latency. Kaempferol-treatment could induce higher levels of IL-1β, IL-4, IL-6, TNF-α and IFN-γ in the serum at 3 dpi which were then declined to normal levels at 5 dpi. Conclusions These results suggested that kaempferol was expected to be a new alternative control measure for PRV infection.